Megens Johanna H A M, de Wit Michel, van Hasselt Peter M, Boelens Jaap Jan, van der Werff Desiree B M, de Graaff Jurgen C
Department of Anesthesiology, Intensive Care and Emergency Medicine, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.
Paediatr Anaesth. 2014 May;24(5):521-7. doi: 10.1111/pan.12370. Epub 2014 Mar 10.
Mucopolysaccharidoses (MPS) are hereditary storage diseases; airway management typically worsens in these patients with the progression of the disease.
OBJECTIVE(S): To assess the incidence of perioperative complications in children with MPS and the impact of enzyme replacement therapy (ERT) followed by hematopoietic stem cell transplantation (HSCT).
The records of patients with MPS treated with ERT followed by HSCT, who received anesthesia at the Wilhelmina Children's Hospital between 2003 and 2012, were reviewed. Data were collected on incidence of perioperative respiratory and cardiovascular complications and the impact of treatment and age.
Nineteen children with MPS were identified (including 17 Hurler patients), who received ERT treatment followed by HSCT. Median age at start of treatment was 14 (range: 7-43) months. Patients were anesthetized 136 times. The incidence of respiratory and cardiovascular complications was 24% and 4%, respectively. Airway management by face mask was difficult in 7%. There were no problems with the laryngeal mask airway. Tracheal intubation was difficult in 25% and failed in 10%; using a video laryngoscope was most successful (89%), followed by classic laryngoscope (67%) and fiber-optic scope (20%). Multivariate logistic regression analyses showed that the incidence of perioperative respiratory problems did not increase with age or decrease after start of treatment.
Perioperative airway management was most successful using a laryngeal mask airway or video laryngoscope. Treatment with ERT followed by HSCT and patient age did not influence the incidence of perioperative respiratory problems.
黏多糖贮积症(MPS)是遗传性贮积病;随着疾病进展,这些患者的气道管理通常会恶化。
评估MPS患儿围手术期并发症的发生率以及酶替代疗法(ERT)联合造血干细胞移植(HSCT)的影响。
回顾了2003年至2012年在威廉明娜儿童医院接受麻醉的接受ERT联合HSCT治疗的MPS患者的记录。收集围手术期呼吸和心血管并发症的发生率以及治疗和年龄的影响的数据。
确定了19例MPS患儿(包括17例Hurler患者),他们接受了ERT治疗后进行了HSCT。开始治疗时的中位年龄为14(范围:7 - 43)个月。患者接受麻醉136次。呼吸和心血管并发症的发生率分别为24%和4%。7%的患者使用面罩进行气道管理困难。喉罩气道没有问题。气管插管困难的发生率为25%,失败率为10%;使用视频喉镜最成功(89%),其次是传统喉镜(67%)和纤维喉镜(20%)。多因素逻辑回归分析表明,围手术期呼吸问题的发生率不会随着年龄增加或治疗开始后降低。
使用喉罩气道或视频喉镜进行围手术期气道管理最成功。ERT联合HSCT治疗和患者年龄不影响围手术期呼吸问题的发生率。